This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Silverman, J. A.
Right arrow Articles by Li, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Silverman, J. A.
Right arrow Articles by Li, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1799-1802, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1799-1802.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Resistance Studies with Daptomycin

Jared A. Silverman,* Nicole Oliver, Ted Andrew, and Tongchuan Li

Cubist Pharmaceuticals, Inc., Cambridge, Massachusetts 02139

Received 8 August 2000/Returned for modification 16 October 2000/Accepted 12 March 2001

We studied the in vitro emergence of resistance to daptomycin using three methods: spontaneous resistance incidence, serial passage in the presence of increasing drug concentrations, and chemical mutagenesis. No spontaneously resistant mutants were obtained for any organism tested (<10-10 for Staphylococcus aureus, <10-9 for Staphylococcus epidermidis, <10-9 for Enterococcus faecalis, <10-9 for Enterococcus faecium, <10-8 for Streptococcus pneumoniae). Population analysis demonstrated that bacterial susceptibility to daptomycin is heterogeneous. Assay results were sensitive to calcium concentration and culture density, both of which can affect apparent resistance rates. Stable S. aureus mutants were isolated by both serial passage in liquid media and chemical mutagenesis. The daptomycin MICs for these isolates were 8- to 32-fold higher than for the parental strain. Many mutants with high MICs (>12.5 µg/ml) had significant growth defects but did not display phenotypes typical of S. aureus small colony variants. The voltage component (Delta psi ) of the bacterial membrane potential was increased in three independent resistant isolates. In vivo data showed that some daptomycin-resistant mutants had lost significant virulence. For other mutants, the degree of in vitro resistance was greater than the change in in vivo susceptibility. These results suggest that infection with some daptomycin-resistant organisms may still be easily treatable.


* Corresponding author. Mailing address: Cubist Pharmaceuticals, Inc., 24 Emily St., Cambridge, MA 02139. Phone: (617) 576-4190. Fax: (617) 576-0232. E-mail: jsilverm{at}cubist.com.


Antimicrobial Agents and Chemotherapy, June 2001, p. 1799-1802, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1799-1802.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Kosowska-Shick, K., Clark, C., Pankuch, G. A., McGhee, P., Dewasse, B., Beachel, L., Appelbaum, P. C. (2009). Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection Studies. Antimicrob. Agents Chemother. 53: 4217-4224 [Abstract] [Full Text]  
  • Murillo, O., Garrigos, C., Pachon, M. E., Euba, G., Verdaguer, R., Cabellos, C., Cabo, J., Gudiol, F., Ariza, J. (2009). Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4252-4257 [Abstract] [Full Text]  
  • Mishra, N. N., Yang, S.-J., Sawa, A., Rubio, A., Nast, C. C., Yeaman, M. R., Bayer, A. S. (2009). Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 2312-2318 [Abstract] [Full Text]  
  • Hachmann, A.-B., Angert, E. R., Helmann, J. D. (2009). Genetic Analysis of Factors Affecting Susceptibility of Bacillus subtilis to Daptomycin. Antimicrob. Agents Chemother. 53: 1598-1609 [Abstract] [Full Text]  
  • Camargo, I. L. B. d. C., Neoh, H.-M., Cui, L., Hiramatsu, K. (2008). Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype. Antimicrob. Agents Chemother. 52: 4289-4299 [Abstract] [Full Text]  
  • Hobbs, J. K., Miller, K., O'Neill, A. J., Chopra, I. (2008). Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62: 1003-1008 [Abstract] [Full Text]  
  • Hidron, A. I., Schuetz, A. N., Nolte, F. S., Gould, C. V., Osborn, M. K. (2008). Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. J Antimicrob Chemother 61: 1394-1396 [Full Text]  
  • Quinn, B., Hussain, S., Malik, M., Drlica, K., Zhao, X. (2007). Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J Antimicrob Chemother 60: 1380-1383 [Abstract] [Full Text]  
  • Goldstein, B. P., Draghi, D. C., Sheehan, D. J., Hogan, P., Sahm, D. F. (2007). Bactericidal Activity and Resistance Development Profiling of Dalbavancin. Antimicrob. Agents Chemother. 51: 1150-1154 [Abstract] [Full Text]  
  • Vouillamoz, J., Moreillon, P., Giddey, M., Entenza, J. M. (2006). Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother 58: 1208-1214 [Abstract] [Full Text]  
  • French, G. L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117 [Abstract] [Full Text]  
  • Wootton, M., MacGowan, A. P., Walsh, T. R. (2006). Comparative Bactericidal Activities of Daptomycin and Vancomycin against Glycopeptide-Intermediate Staphylococcus aureus (GISA) and Heterogeneous GISA Isolates. Antimicrob. Agents Chemother. 50: 4195-4197 [Abstract] [Full Text]  
  • Diederen, B. M. W., van Duijn, I., Willemse, P., Kluytmans, J. A. J. W. (2006). In Vitro Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus, Including Heterogeneously Glycopeptide-Resistant Strains.. Antimicrob. Agents Chemother. 50: 3189-3191 [Abstract] [Full Text]  
  • Jevitt, L. A., Thorne, G. M., Traczewski, M. M., Jones, R. N., McGowan, J. E. Jr., Tenover, F. C., Brown, S. D. (2006). Multicenter Evaluation of the Etest and Disk Diffusion Methods for Differentiating Daptomycin-Susceptible from Non-Daptomycin-Susceptible Staphylococcus aureus Isolates.. J. Clin. Microbiol. 44: 3098-3104 [Abstract] [Full Text]  
  • Green, M. R, Anasetti, C., Sandin, R. L, Rolfe, N. E, Greene, J. N (2006). Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans. J Oncol Pharm Pract 12: 179-181 [Abstract]  
  • Denis, O., Deplano, A., Nonhoff, C., Hallin, M., De Ryck, R., Vanhoof, R., De Mendonca, R., Struelens, M. J. (2006). In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals.. Antimicrob. Agents Chemother. 50: 2680-2685 [Abstract] [Full Text]  
  • Tyrrell, K. L., Citron, D. M., Warren, Y. A., Fernandez, H. T., Merriam, C. V., Goldstein, E. J. C. (2006). In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.. Antimicrob. Agents Chemother. 50: 2728-2731 [Abstract] [Full Text]  
  • Friedman, L., Alder, J. D., Silverman, J. A. (2006). Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2137-2145 [Abstract] [Full Text]  
  • Jorgensen, J. H., Crawford, S. A. (2006). Assessment of Two Commercial Susceptibility Test Methods for Determination of Daptomycin MICs.. J. Clin. Microbiol. 44: 2126-2129 [Abstract] [Full Text]  
  • Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R. C. Jr., Eliopoulos, G. M. (2006). Induction of Daptomycin Heterogeneous Susceptibility in Staphylococcus aureus by Exposure to Vancomycin.. Antimicrob. Agents Chemother. 50: 1581-1585 [Abstract] [Full Text]  
  • Marty, F. M., Yeh, W. W., Wennersten, C. B., Venkataraman, L., Albano, E., Alyea, E. P., Gold, H. S., Baden, L. R., Pillai, S. K. (2006). Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis. J. Clin. Microbiol. 44: 595-597 [Abstract] [Full Text]  
  • Skiest, D. J. (2006). Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin. J. Clin. Microbiol. 44: 655-656 [Abstract] [Full Text]  
  • Lesho, E. P., Wortmann, G. W., Craft, D., Moran, K. A. (2006). De Novo Daptomycin Nonsusceptibility in a Clinical Isolate. J. Clin. Microbiol. 44: 673-673 [Full Text]  
  • Bogdanovich, T., Ednie, L. M., Shapiro, S., Appelbaum, P. C. (2005). Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin. Antimicrob. Agents Chemother. 49: 4210-4219 [Abstract] [Full Text]  
  • Hayden, M. K., Rezai, K., Hayes, R. A., Lolans, K., Quinn, J. P., Weinstein, R. A. (2005). Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus. J. Clin. Microbiol. 43: 5285-5287 [Abstract] [Full Text]  
  • Long, J. K., Choueiri, T. K., Hall, G. S., Avery, R. K., Sekeres, M. A. (2005). Daptomycin-Resistant Enterococcus faecium in a Patient With Acute Myeloid Leukemia. Mayo Clin Proc. 80: 1215-1216 [Abstract]  
  • Schriever, C. A., Fernandez, C., Rodvold, K. A., Danziger, L. H. (2005). Daptomycin: A novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm 62: 1145-1158 [Abstract] [Full Text]  
  • Miao, V., Coeffet-LeGal, M.-F., Brian, P., Brost, R., Penn, J., Whiting, A., Martin, S., Ford, R., Parr, I., Bouchard, M., Silva, C. J., Wrigley, S. K., Baltz, R. H. (2005). Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 151: 1507-1523 [Abstract] [Full Text]  
  • Steenbergen, J. N., Alder, J., Thorne, G. M., Tally, F. P. (2005). Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55: 283-288 [Abstract] [Full Text]  
  • Lai, J.-J., Brodeur, S. K (2004). Physical and Chemical Compatibility of Daptomycin with Nine Medications. The Annals of Pharmacotherapy 38: 1612-1616 [Abstract] [Full Text]  
  • Dvorchik, B., Arbeit, R. D., Chung, J., Liu, S., Knebel, W., Kastrissios, H. (2004). Population Pharmacokinetics of Daptomycin. Antimicrob. Agents Chemother. 48: 2799-2807 [Abstract] [Full Text]  
  • Dvorchik, B. (2004). Moderate Liver Impairment Has No Influence on Daptomycin Pharmacokinetics. J Clin Pharmacol 44: 715-722 [Abstract] [Full Text]  
  • Alder, J., Li, T., Yu, D., Morton, L., Silverman, J., Zhang, X.-X., Critchley, I., Thorne, G. (2003). Analysis of Daptomycin Efficacy and Breakpoint Standards in a Murine Model of Enterococcus faecalis and Enterococcus faecium Renal Infection. Antimicrob. Agents Chemother. 47: 3561-3566 [Abstract] [Full Text]  
  • Silverman, J. A., Perlmutter, N. G., Shapiro, H. M. (2003). Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 2538-2544 [Abstract] [Full Text]  
  • Laganas, V., Alder, J., Silverman, J. A. (2003). In Vitro Bactericidal Activities of Daptomycin against Staphylococcus aureus and Enterococcus faecalis Are Not Mediated by Inhibition of Lipoteichoic Acid Biosynthesis. Antimicrob. Agents Chemother. 47: 2682-2684 [Abstract] [Full Text]  
  • Vaudaux, P., Francois, P., Bisognano, C., Li, D., Lew, D. P., Schrenzel, J. (2003). Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother 52: 89-95 [Abstract] [Full Text]  
  • Critchley, I. A., Blosser-Middleton, R. S., Jones, M. E., Thornsberry, C., Sahm, D. F., Karlowsky, J. A. (2003). Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001. Antimicrob. Agents Chemother. 47: 1689-1693 [Abstract] [Full Text]  
  • Sakoulas, G., Eliopoulos, G. M., Alder, J., Eliopoulos, C. T. (2003). Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus. Antimicrob. Agents Chemother. 47: 1714-1718 [Abstract] [Full Text]  
  • Critchley, I. A., Draghi, D. C., Sahm, D. F., Thornsberry, C., Jones, M. E., Karlowsky, J. A. (2003). Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. J Antimicrob Chemother 51: 639-649 [Abstract] [Full Text]  
  • Oliva, B., Miller, K., Caggiano, N., O'Neill, A. J., Cuny, G. D., Hoemann, M. Z., Hauske, J. R., Chopra, I. (2003). Biological Properties of Novel Antistaphylococcal Quinoline-Indole Agents. Antimicrob. Agents Chemother. 47: 458-466 [Abstract] [Full Text]  
  • Kaatz, G. W., Moudgal, V. V., Seo, S. M., Kristiansen, J. E. (2003). Phenothiazines and Thioxanthenes Inhibit Multidrug Efflux Pump Activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 719-726 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2003). In Vitro Activities of Daptomycin, Vancomycin, Quinupristin- Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates. Antimicrob. Agents Chemother. 47: 337-341 [Abstract] [Full Text]